CA2673837C - Storage and dispensing devices for administration of oral transmucosal dosage forms - Google Patents
Storage and dispensing devices for administration of oral transmucosal dosage forms Download PDFInfo
- Publication number
- CA2673837C CA2673837C CA2673837A CA2673837A CA2673837C CA 2673837 C CA2673837 C CA 2673837C CA 2673837 A CA2673837 A CA 2673837A CA 2673837 A CA2673837 A CA 2673837A CA 2673837 C CA2673837 C CA 2673837C
- Authority
- CA
- Canada
- Prior art keywords
- cartridge
- drug
- tablet
- dispensing device
- sufentanil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002552 dosage form Substances 0.000 title abstract description 475
- 238000003860 storage Methods 0.000 title description 9
- 239000003814 drug Substances 0.000 claims abstract description 384
- 229940079593 drug Drugs 0.000 claims abstract description 376
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims abstract description 220
- 229960004739 sufentanil Drugs 0.000 claims abstract description 200
- 230000003287 optical effect Effects 0.000 claims description 10
- 239000004033 plastic Substances 0.000 claims description 9
- 229920003023 plastic Polymers 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 6
- 230000000704 physical effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 79
- 238000000034 method Methods 0.000 abstract description 50
- 208000002193 Pain Diseases 0.000 description 71
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 70
- 238000009472 formulation Methods 0.000 description 65
- 239000003826 tablet Substances 0.000 description 65
- 230000036407 pain Effects 0.000 description 48
- 210000003296 saliva Anatomy 0.000 description 48
- 210000002200 mouth mucosa Anatomy 0.000 description 43
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 40
- 229960001391 alfentanil Drugs 0.000 description 40
- 238000011282 treatment Methods 0.000 description 37
- 241000282472 Canis lupus familiaris Species 0.000 description 35
- 230000036470 plasma concentration Effects 0.000 description 35
- 230000001225 therapeutic effect Effects 0.000 description 35
- 239000013543 active substance Substances 0.000 description 30
- 210000002381 plasma Anatomy 0.000 description 30
- 241000282414 Homo sapiens Species 0.000 description 29
- 238000010521 absorption reaction Methods 0.000 description 29
- 239000007788 liquid Substances 0.000 description 29
- 229960002428 fentanyl Drugs 0.000 description 26
- 238000003379 elimination reaction Methods 0.000 description 22
- 210000004379 membrane Anatomy 0.000 description 22
- 239000012528 membrane Substances 0.000 description 22
- 210000000214 mouth Anatomy 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 21
- 230000008030 elimination Effects 0.000 description 21
- 239000002274 desiccant Substances 0.000 description 20
- 229940021271 fentora Drugs 0.000 description 20
- 230000002496 gastric effect Effects 0.000 description 20
- 238000001990 intravenous administration Methods 0.000 description 19
- 208000005298 acute pain Diseases 0.000 description 18
- 239000002585 base Substances 0.000 description 18
- 229940060201 actiq Drugs 0.000 description 17
- 238000012377 drug delivery Methods 0.000 description 17
- 230000003628 erosive effect Effects 0.000 description 17
- 239000000463 material Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- 238000003032 molecular docking Methods 0.000 description 15
- 239000000227 bioadhesive Substances 0.000 description 13
- 239000010408 film Substances 0.000 description 13
- -1 troches Substances 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 230000009747 swallowing Effects 0.000 description 12
- 241001474791 Proboscis Species 0.000 description 11
- 210000003128 head Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 208000000003 Breakthrough pain Diseases 0.000 description 10
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 10
- 238000004891 communication Methods 0.000 description 10
- 239000000039 congener Substances 0.000 description 10
- 239000011888 foil Substances 0.000 description 10
- 238000007726 management method Methods 0.000 description 10
- 229960003394 remifentanil Drugs 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- OJCZPLDERGDQRJ-UHFFFAOYSA-N Sufentanil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 OJCZPLDERGDQRJ-UHFFFAOYSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000011833 dog model Methods 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 239000007937 lozenge Substances 0.000 description 9
- 229940005483 opioid analgesics Drugs 0.000 description 9
- 229960001204 sufentanil citrate Drugs 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 8
- 239000000853 adhesive Substances 0.000 description 8
- 230000001070 adhesive effect Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000002250 absorbent Substances 0.000 description 7
- 230000002745 absorbent Effects 0.000 description 7
- 230000035587 bioadhesion Effects 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000006186 oral dosage form Substances 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 210000000707 wrist Anatomy 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 230000036592 analgesia Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 238000001647 drug administration Methods 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 229940028426 sufenta Drugs 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000000017 hydrogel Substances 0.000 description 5
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 206010049244 Ankyloglossia congenital Diseases 0.000 description 4
- 208000000094 Chronic Pain Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 206010051259 Therapy naive Diseases 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 210000003097 mucus Anatomy 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 229940023488 pill Drugs 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 3
- 206010039897 Sedation Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- YDSDEBIZUNNPOB-UHFFFAOYSA-N carfentanil Chemical compound C1CN(CCC=2C=CC=CC=2)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 YDSDEBIZUNNPOB-UHFFFAOYSA-N 0.000 description 3
- 229950004689 carfentanil Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000599 controlled substance Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000013583 drug formulation Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 229950010274 lofentanil Drugs 0.000 description 3
- IMYHGORQCPYVBZ-NLFFAJNJSA-N lofentanil Chemical compound CCC(=O)N([C@@]1([C@@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 IMYHGORQCPYVBZ-NLFFAJNJSA-N 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- BJZZDOLVVLWFHN-UHFFFAOYSA-N mirfentanil Chemical compound C=1C=COC=1C(=O)N(C=1N=CC=NC=1)C(CC1)CCN1CCC1=CC=CC=C1 BJZZDOLVVLWFHN-UHFFFAOYSA-N 0.000 description 3
- 229950002136 mirfentanil Drugs 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- 102000051367 mu Opioid Receptors Human genes 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- HGASFNYMVGEKTF-UHFFFAOYSA-N octan-1-ol;hydrate Chemical compound O.CCCCCCCCO HGASFNYMVGEKTF-UHFFFAOYSA-N 0.000 description 3
- 229940124583 pain medication Drugs 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000036280 sedation Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- RJSCINHYBGMIFT-UHFFFAOYSA-N trefentanil Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(C=1C=CC=CC=1)N(C(=O)CC)C1=CC=CC=C1F RJSCINHYBGMIFT-UHFFFAOYSA-N 0.000 description 3
- 229950003235 trefentanil Drugs 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 108020001612 μ-opioid receptors Proteins 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000219823 Medicago Species 0.000 description 2
- 208000012266 Needlestick injury Diseases 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 241000931888 Pyxis Species 0.000 description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
- 206010038678 Respiratory depression Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000002457 bidirectional effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000007580 dry-mixing Methods 0.000 description 2
- 229940022646 fentanyl buccal tablet Drugs 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003402 opiate agonist Substances 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000013062 quality control Sample Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 239000012808 vapor phase Substances 0.000 description 2
- KJLPSBMDOIVXSN-UHFFFAOYSA-N 4-[4-[2-[4-(3,4-dicarboxyphenoxy)phenyl]propan-2-yl]phenoxy]phthalic acid Chemical compound C=1C=C(OC=2C=C(C(C(O)=O)=CC=2)C(O)=O)C=CC=1C(C)(C)C(C=C1)=CC=C1OC1=CC=C(C(O)=O)C(C(O)=O)=C1 KJLPSBMDOIVXSN-UHFFFAOYSA-N 0.000 description 1
- 208000032484 Accidental exposure to product Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000012488 Opiate Overdose Diseases 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 208000000399 Procedural Pain Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 231100000818 accidental exposure Toxicity 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 208000029771 childhood onset asthma Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229940125368 controlled substance Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000004955 epithelial membrane Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000002648 laminated material Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 229940124636 opioid drug Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940051877 other opioids in atc Drugs 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000033300 receptor internalization Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000003421 short acting drug Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/0015—Devices specially adapted for taking medicines
- A61J7/0023—Spoons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/0015—Devices specially adapted for taking medicines
- A61J7/0046—Cups, bottles or bags
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/0015—Devices specially adapted for taking medicines
- A61J7/0053—Syringes, pipettes or oral dispensers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J15/00—Feeding-tubes for therapeutic purposes
- A61J15/0011—Feeding-tubes for delivery of nourishment to the mouth; Mouth pieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/0076—Medicament distribution means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/02—Pill counting devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
- A61J7/0409—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers
- A61J7/0418—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers with electronic history memory
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
- A61J7/0409—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers
- A61J7/0427—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers with direct interaction with a dispensing or delivery system
- A61J7/0445—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers with direct interaction with a dispensing or delivery system for preventing drug dispensing during a predetermined time period
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Medical Informatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/650,174 US8202535B2 (en) | 2006-01-06 | 2007-01-05 | Small-volume oral transmucosal dosage forms |
| US11/650,230 US8357114B2 (en) | 2006-01-06 | 2007-01-05 | Drug dispensing device with flexible push rod |
| US11/650,174 | 2007-01-05 | ||
| US11/650,230 | 2007-01-05 | ||
| US11/825,212 | 2007-07-03 | ||
| US11/825,212 US9066847B2 (en) | 2007-01-05 | 2007-07-03 | Storage and dispensing devices for administration of oral transmucosal dosage forms |
| US11/980,216 | 2007-10-30 | ||
| US11/980,216 US9289583B2 (en) | 2006-01-06 | 2007-10-30 | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
| PCT/US2007/089017 WO2008085764A1 (en) | 2007-01-05 | 2007-12-28 | Storage and dispensing devices for administration of oral transmucosal dosage forms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2673837A1 CA2673837A1 (en) | 2008-07-17 |
| CA2673837C true CA2673837C (en) | 2015-11-24 |
Family
ID=39456236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2673837A Active CA2673837C (en) | 2007-01-05 | 2007-12-28 | Storage and dispensing devices for administration of oral transmucosal dosage forms |
Country Status (4)
| Country | Link |
|---|---|
| JP (3) | JP5503292B2 (enExample) |
| KR (1) | KR101445891B1 (enExample) |
| CA (1) | CA2673837C (enExample) |
| WO (1) | WO2008085764A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
| US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US8753308B2 (en) | 2006-01-06 | 2014-06-17 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
| US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| CA2673837C (en) * | 2007-01-05 | 2015-11-24 | Acelrx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
| US8945592B2 (en) * | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
| WO2010107761A1 (en) | 2009-03-18 | 2010-09-23 | Acelrx Pharmaceuticals, Inc. | Improved storage and dispensing devices for administration of oral transmucosal dosage forms |
| US20110288128A1 (en) * | 2010-05-21 | 2011-11-24 | Acelrx Pharmaceuticals, Inc. | Oral Transmucosal Administration of Sufentanil |
| GB2520315B (en) | 2013-11-15 | 2017-12-06 | Babyhappy Ltd | Oral Syringes |
| WO2016106329A1 (en) | 2014-12-23 | 2016-06-30 | Acelrx Pharmaceuticals, Inc. | Systems, devices and methods for dispensing oral transmucosal dosage forms |
| US10737027B2 (en) | 2015-01-27 | 2020-08-11 | Shl Medical Ag | Medicament delivery device |
| CN106236575B (zh) * | 2016-08-24 | 2019-01-11 | 合肥凌翔信息科技有限公司 | 一种具有生命体征监测功能的智能药盒 |
| US11116657B2 (en) | 2017-02-02 | 2021-09-14 | Zoll Circulation, Inc. | Devices, systems and methods for endovascular temperature control |
| US11185440B2 (en) | 2017-02-02 | 2021-11-30 | Zoll Circulation, Inc. | Devices, systems and methods for endovascular temperature control |
| GB201817978D0 (en) | 2018-11-02 | 2018-12-19 | Ondosis Ab | Delivery device for drug pellets |
| US11585042B2 (en) | 2020-09-30 | 2023-02-21 | Haier Us Appliance Solutions, Inc. | Dryer appliance with additive dispenser |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2621655A (en) * | 1951-10-11 | 1952-12-16 | Kenneth L Gothard | Tablet dispensing gun |
| US4474308A (en) * | 1982-09-30 | 1984-10-02 | Michel Bergeron | Tablet ejector |
| US4981468A (en) * | 1989-02-17 | 1991-01-01 | Eli Lilly And Company | Delivery device for orally administered therapeutic agents |
| JPH02121039U (enExample) * | 1989-03-17 | 1990-10-01 | ||
| US5292307A (en) * | 1992-09-16 | 1994-03-08 | Dolzine Theodore W | Dispensing package for unit dosage |
| US5507277A (en) * | 1993-01-29 | 1996-04-16 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activateddispenser |
| AUPN603895A0 (en) * | 1995-10-19 | 1995-11-09 | University Of Queensland, The | Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids |
| JP2000053174A (ja) * | 1998-08-04 | 2000-02-22 | Lion Corp | 小形物品用容器 |
| AU2001234005B2 (en) * | 2000-02-28 | 2006-01-19 | Pharmakodex Limited | Improvements in or relating to the delivery of oral drugs |
| GB2368061B (en) * | 2000-10-20 | 2005-05-11 | Gw Pharmaceuticals Ltd | Dose dispensing apparatus |
| GB0108215D0 (en) | 2001-04-02 | 2001-05-23 | Glaxo Group Ltd | Medicament dispenser |
| US7044302B2 (en) * | 2001-09-19 | 2006-05-16 | Avancen, Inc. | Patient controlled timed oral medication dispenser |
| EP2123318B1 (en) * | 2002-02-22 | 2016-01-13 | GW Pharma Limited | Dose dispensing system and apparatus |
| GB0209782D0 (en) * | 2002-04-29 | 2002-06-05 | Glaxo Group Ltd | Medicament dispenser |
| JP4740589B2 (ja) * | 2002-04-29 | 2011-08-03 | グラクソ グループ リミテッド | 警告システム |
| KR20050096950A (ko) * | 2003-01-31 | 2005-10-06 | 오렉쏘 에이비 | 신속-작용 약학 조성물 |
| WO2004100859A1 (ja) * | 2003-05-14 | 2004-11-25 | Kureha Corporation | 経口摂取用固形成形物の嚥下用収容体、その収容体用の容器、及び嚥下方法 |
| US20050150489A1 (en) * | 2004-01-12 | 2005-07-14 | Steve Dunfield | Dispensing medicaments based on rates of medicament action |
| WO2005072803A1 (en) * | 2004-01-16 | 2005-08-11 | Biodel, Inc. | Sublingual drug delivery device |
| RS50817B (sr) * | 2004-03-30 | 2010-08-31 | Euro-Celtique S.A. | Dozni oblik otporan na promene koji sadrži adsorbenti i sredstvo sa suprotnim dejstvom |
| WO2006023985A2 (en) * | 2004-08-23 | 2006-03-02 | Remote Clinical Solutions, Inc. | System and method for modifying a fluid for oral administration |
| GB0420016D0 (en) * | 2004-09-09 | 2004-10-13 | Leuven K U Res & Dev | Controlled release oral delivery system |
| FR2883179B1 (fr) * | 2005-03-18 | 2009-04-17 | Ethypharm Sa | Comprime enrobe |
| US8357114B2 (en) | 2006-01-06 | 2013-01-22 | Acelrx Pharmaceuticals, Inc. | Drug dispensing device with flexible push rod |
| CA2673837C (en) * | 2007-01-05 | 2015-11-24 | Acelrx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
-
2007
- 2007-12-28 CA CA2673837A patent/CA2673837C/en active Active
- 2007-12-28 KR KR1020097016352A patent/KR101445891B1/ko not_active Expired - Fee Related
- 2007-12-28 WO PCT/US2007/089017 patent/WO2008085764A1/en not_active Ceased
- 2007-12-28 JP JP2009544899A patent/JP5503292B2/ja active Active
-
2013
- 2013-11-28 JP JP2013246090A patent/JP5876024B2/ja not_active Expired - Fee Related
-
2015
- 2015-06-02 JP JP2015111874A patent/JP6138196B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008085764B1 (en) | 2008-10-16 |
| KR101445891B1 (ko) | 2014-10-02 |
| WO2008085764A1 (en) | 2008-07-17 |
| JP2015155023A (ja) | 2015-08-27 |
| CA2673837A1 (en) | 2008-07-17 |
| JP2010531153A (ja) | 2010-09-24 |
| JP5503292B2 (ja) | 2014-05-28 |
| JP5876024B2 (ja) | 2016-03-02 |
| JP2014042845A (ja) | 2014-03-13 |
| JP6138196B2 (ja) | 2017-05-31 |
| KR20090096747A (ko) | 2009-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10507180B2 (en) | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | |
| US8499966B2 (en) | Method of moving a delivery member of a dispensing device for administration of oral transmucosal dosage forms | |
| CA2673837C (en) | Storage and dispensing devices for administration of oral transmucosal dosage forms | |
| US9289583B2 (en) | Methods for administering small volume oral transmucosal dosage forms using a dispensing device | |
| US10709881B2 (en) | Apparatus for administering small volume oral transmucosal dosage forms | |
| CN101730516A (zh) | 用于口腔跨粘膜剂型给药的存储和分配装置 | |
| CN101621994B (zh) | 用于治疗疼痛的含舒芬太尼的小量口腔跨粘膜剂型 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| EEER | Examination request |
Effective date: 20121227 |